• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

热休克蛋白90(HSP90)在多客户相互作用组中稳定B细胞受体激酶:PU-H71在细胞保护微环境中诱导慢性淋巴细胞白血病(CLL)细胞凋亡。

HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.

作者信息

Guo A, Lu P, Lee J, Zhen C, Chiosis G, Wang Y L

机构信息

Division of Genomic and Molecular Pathology, Department of Pathology, University of Chicago and.

Program in Chemical Biology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Oncogene. 2017 Jun 15;36(24):3441-3449. doi: 10.1038/onc.2016.494. Epub 2017 Jan 23.

DOI:10.1038/onc.2016.494
PMID:28114285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5645670/
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells in the hematopoietic system and lymphoid tissues. Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in the treatment of the disease, the underlying mechanisms leading to BCR over-activity in CLL are not fully understood. In this study, we found that HSP90, a highly conserved molecular chaperone, is overexpressed in CLL compared with resting B cells. HSP90 overexpression is accompanied by the overexpression of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT. Chemical and immune-precipitation demonstrated that these BCR constituents are present in a multi-client chaperone complex with HSP90. Inhibition of HSP90 with PU-H71 destabilized the BCR kinases and caused apoptosis of CLL cells through the mitochondrial apoptotic pathway. Further, PU-H71 induced apoptosis in the presence of stromal co-culture or cytoprotective survival signals. Finally, genetic knockdown of HSP90 and its client AKT, but not BTK, reduced CLL viability. Overall, our study suggests that the chaperone function of HSP90 contributes to the over-activity of the BCR signaling in CLL and inhibition of HSP90 has the potential to achieve a multi-targeting effect. Thus, HSP90 inhibition may be explored to prevent or overcome drug resistance to single targeting agents.

摘要

慢性淋巴细胞白血病(CLL)的特征是B细胞在造血系统和淋巴组织中积聚。尽管靶向B细胞受体(BCR)途径的抑制剂已成功用于治疗该疾病,但导致CLL中BCR过度活化的潜在机制尚未完全明确。在本研究中,我们发现,与静息B细胞相比,高度保守的分子伴侣热休克蛋白90(HSP90)在CLL中过表达。HSP90的过表达伴随着包括LYN、脾酪氨酸激酶、布鲁顿酪氨酸激酶和AKT在内的几种BCR激酶的过表达。化学沉淀和免疫沉淀表明,这些BCR成分与HSP90存在于多客户伴侣复合物中。用PU-H71抑制HSP90会使BCR激酶不稳定,并通过线粒体凋亡途径导致CLL细胞凋亡。此外,PU-H71在存在基质共培养或细胞保护存活信号的情况下诱导细胞凋亡。最后,对HSP90及其客户蛋白AKT而非BTK进行基因敲低可降低CLL的活力。总体而言,我们的研究表明,HSP90的伴侣功能有助于CLL中BCR信号的过度活化,抑制HSP90有可能实现多靶点效应。因此,可探索抑制HSP90以预防或克服对单一靶向药物的耐药性。

相似文献

1
HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.热休克蛋白90(HSP90)在多客户相互作用组中稳定B细胞受体激酶:PU-H71在细胞保护微环境中诱导慢性淋巴细胞白血病(CLL)细胞凋亡。
Oncogene. 2017 Jun 15;36(24):3441-3449. doi: 10.1038/onc.2016.494. Epub 2017 Jan 23.
2
Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.PU-H71对热休克蛋白90的抑制作用通过内质网应激和线粒体途径诱导癌细胞凋亡,并克服了Bcl-2所赋予的耐药性。
Biochim Biophys Acta. 2013 Jun;1833(6):1356-66. doi: 10.1016/j.bbamcr.2013.02.014. Epub 2013 Feb 26.
3
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.脾酪氨酸激酶抑制可预防慢性淋巴细胞白血病中趋化因子和整合素介导的基质保护作用。
Blood. 2010 Jun 3;115(22):4497-506. doi: 10.1182/blood-2009-07-233692. Epub 2010 Mar 24.
4
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.KRAS 突变癌细胞中 HSP90 抑制耐药机制的前瞻性鉴定。
Oncotarget. 2017 Jan 31;8(5):7678-7690. doi: 10.18632/oncotarget.13841.
5
Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.达沙替尼抑制慢性淋巴细胞白血病中的 B 细胞受体信号,但需要新的联合治疗方法来克服额外的生存微环境信号。
Br J Haematol. 2011 Apr;153(2):199-211. doi: 10.1111/j.1365-2141.2010.08507.x. Epub 2011 Feb 24.
6
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.ROR1 失稳增强伊布替尼对体内慢性淋巴细胞白血病的活性。
Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.
7
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.通过单细胞分析确定非霍奇金淋巴瘤中B细胞受体信号传导的不同模式。
Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.
8
Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.靶向热休克因子1破坏慢性淋巴细胞白血病中热休克蛋白90的伴侣功能。
Oncotarget. 2015 Oct 13;6(31):31767-79. doi: 10.18632/oncotarget.5167.
9
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.药物蛋白质组学确定弥漫性大B细胞淋巴瘤的联合治疗靶点。
J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.
10
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.酪氨酸激酶Syk通过蛋白激酶Cδ(PKCδ)和蛋白酶体依赖性的Mcl-1表达调控,调节慢性淋巴细胞白血病B细胞的存活。
Oncogene. 2009 Sep 17;28(37):3261-73. doi: 10.1038/onc.2009.179. Epub 2009 Jul 6.

引用本文的文献

1
Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches.白血病和淋巴瘤中的热休克蛋白:创新治疗方法的多靶点
Cancers (Basel). 2023 Feb 3;15(3):984. doi: 10.3390/cancers15030984.
2
Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer.Hsp90 与癌症的 Tsc1 和 FNIP 共伴侣之间新的联系。
Biomolecules. 2022 Jul 1;12(7):928. doi: 10.3390/biom12070928.
3
Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation.热休克蛋白 90 是同种异体移植中抗排斥治疗的一个新的潜在靶点。

本文引用的文献

1
BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.慢性淋巴细胞白血病中抗IgM和抗IgD刺激后的BCR和趋化因子反应
Ann Hematol. 2016 Dec;95(12):1979-1988. doi: 10.1007/s00277-016-2788-6. Epub 2016 Aug 20.
2
Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.用于研究疾病中 HSP90 和 HSP70 相关机制的化学工具。
Cell Chem Biol. 2016 Jan 21;23(1):158-172. doi: 10.1016/j.chembiol.2015.12.006.
3
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Cell Stress Chaperones. 2022 Jul;27(4):337-351. doi: 10.1007/s12192-022-01272-2. Epub 2022 Apr 9.
4
AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.慢性淋巴细胞白血病中的AID:疾病进展过程中的诱导与作用
Front Oncol. 2021 May 10;11:634383. doi: 10.3389/fonc.2021.634383. eCollection 2021.
5
Heat Shock Proteins in Lymphoma Immunotherapy.热休克蛋白在淋巴瘤免疫治疗中的作用。
Front Immunol. 2021 Mar 18;12:660085. doi: 10.3389/fimmu.2021.660085. eCollection 2021.
6
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.依鲁替尼和维奈托克靶向 CLL 细胞的不同亚群:对残留疾病清除的影响。
Blood Cancer J. 2021 Feb 18;11(2):39. doi: 10.1038/s41408-021-00429-z.
7
HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells.HSP90过表达增强慢性淋巴细胞白血病细胞中的B细胞受体和成纤维细胞生长因子受体存活信号。
Oncotarget. 2020 Jun 2;11(22):2037-2046. doi: 10.18632/oncotarget.27409.
8
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.人类首例以 Epichaperome 为靶点的 PET 在癌症患者中的试验。
Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704. Epub 2020 May 4.
9
Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.热休克蛋白:癌症发展的作用因子和癌症治疗中的治疗靶点。
Cells. 2019 Dec 24;9(1):60. doi: 10.3390/cells9010060.
10
HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.HSP90 抑制剂 PU-H71 增加转移至内脏器官的乳腺癌细胞的放射敏感性,并改变炎症介质的水平。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):253-262. doi: 10.1007/s00210-019-01725-z. Epub 2019 Sep 14.
未突变的慢性淋巴细胞白血病中依赖布鲁顿酪氨酸激酶(BTK)的细胞增殖增强,使其对依鲁替尼的敏感性增加。
Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727.
4
Chronic lymphocytic leukemia (CLL)-Then and now.慢性淋巴细胞白血病(CLL)——过去与现在。
Am J Hematol. 2016 Mar;91(3):330-40. doi: 10.1002/ajh.24282.
5
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species.急性髓系白血病中过度活跃的信号体导致对肿瘤特异性热休克蛋白90亚型的依赖。
Cell Rep. 2015 Dec 15;13(10):2159-73. doi: 10.1016/j.celrep.2015.10.073. Epub 2015 Nov 25.
6
Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.塞杜拉替尼是一种新型的SYK/JAK双重激酶抑制剂,对ABC和GCB两种类型的弥漫性大B细胞淋巴瘤均具有广泛的抗肿瘤活性。
Oncotarget. 2015 Dec 22;6(41):43881-96. doi: 10.18632/oncotarget.6316.
7
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.药物蛋白质组学确定弥漫性大B细胞淋巴瘤的联合治疗靶点。
J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.
8
Mutations driving CLL and their evolution in progression and relapse.驱动慢性淋巴细胞白血病的突变及其在疾病进展和复发中的演变。
Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14.
9
Non-coding recurrent mutations in chronic lymphocytic leukaemia.慢性淋巴细胞白血病中的非编码重现性突变。
Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22.
10
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.在依鲁替尼耐药的慢性淋巴细胞白血病中获得的磷脂酶Cγ2的超形态突变赋予B细胞受体激活对布鲁顿酪氨酸激酶的独立性。
Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13.